A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Carcinoma, Non-Small-Cell Lung
  • ErbB Receptors
  • Lung Neoplasms
  • Quinazolines
  • Quinazolinones

abstract

  • Dacomitinib demonstrated preliminary activity and acceptable tolerability in heavily pretreated patients, and may offer benefit in molecularly defined patient subsets.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4164026

Digital Object Identifier (DOI)

  • 10.1002/cncr.28561

PubMed ID

  • 24501009

Additional Document Info

start page

  • 1145

end page

  • 54

volume

  • 120

number

  • 8